Yes. A drug-resistant fungus called Candida auris has been spreading rapidly across the United States and globally, and health authorities are paying close attention. U.S. clinical cases jumped from 48 in 2016 to 6,304 in 2024, with more than 17,000 total clinical cases reported over that period. The fungus primarily threatens hospitalized patients and people with weakened immune systems, not the general public, but its speed of spread and resistance to common antifungal medications make it a serious concern.
What Is Candida Auris?
Candida auris is a type of yeast that can cause severe bloodstream, wound, and organ infections. First identified in 2009 in Japan, it has since appeared on every inhabited continent. What sets it apart from other fungal infections is a combination of traits that make it unusually dangerous in healthcare settings: it resists multiple antifungal drugs, it’s difficult to identify with standard lab equipment, and it survives on hospital surfaces for months.
The CDC classifies it as an “urgent threat,” the highest level of concern for antibiotic and antifungal resistance. The World Health Organization placed it in the “critical priority” group on its first-ever fungal priority pathogens list, alongside just three other species.
How Fast It’s Spreading
The growth curve is steep. Annual U.S. clinical cases have roughly doubled every one to two years:
- 2016: 48 cases
- 2019: 477 cases
- 2021: 1,559 cases
- 2023: 4,523 cases
- 2024: 6,304 cases
On top of those clinical cases, more than 35,000 additional “screening cases” have been identified, meaning the fungus was found on patients’ skin or in their bodies without causing active infection. These colonized individuals can still spread it to others, which is one reason outbreaks in hospitals and nursing homes are so hard to contain.
Geographically, the heaviest burden falls on California (2,557 cumulative cases), New York (2,255), Illinois (2,208), Florida (1,956), and Nevada (1,740). But it has now been reported in more than 40 states. Only a handful of states, including Alaska, Kansas, Maine, and Wyoming, have reported zero cases.
Why It’s So Hard to Treat
Most fungal infections respond to one of three main classes of antifungal drugs. Candida auris frequently resists the most commonly used class, and some strains resist two or even all three. When a patient has a strain that resists every available treatment option, clinicians have very little to work with. Testing volume for the fungus increased 1.5-fold between 2022 and 2023 alone, reflecting how rapidly it’s showing up in hospitals across the country.
Adding to the problem, standard lab equipment frequently misidentifies it as a different, less dangerous yeast species. Commonly used identification systems in hospital labs can mistake it for at least a dozen other organisms. Specialized testing, such as specific DNA-based methods, is needed for an accurate diagnosis. A misidentified case means the patient may not receive the right treatment and the hospital may not activate the infection control measures needed to prevent spread.
Who Is at Risk
Candida auris is not a threat to most healthy people. It targets patients who are already seriously ill, typically those in hospitals or long-term care facilities. The people most vulnerable share certain characteristics: they’ve had long hospital stays, they have central lines or catheters, they’ve recently received broad-spectrum antibiotics or antifungals, or their immune systems are compromised by conditions like diabetes, cancer treatment, or organ transplantation.
Age matters too. Invasive Candida infections in general are most common in adults over 65 and in infants under one year old. These groups tend to have weaker immune defenses and more frequent contact with healthcare settings where the fungus circulates.
For those who do develop an invasive infection, the stakes are high. Patients with Candida auris bloodstream infections have an estimated crude mortality rate of 47%. Even among those with non-bloodstream infections, the rate is around 31%. These numbers reflect the fact that patients who contract it are often already very sick, but the fungus’s drug resistance makes an already dangerous situation worse.
How It Spreads in Hospitals
Candida auris spreads primarily through direct contact with contaminated surfaces or with colonized patients in healthcare facilities. Unlike many fungi, it clings stubbornly to bed rails, medical equipment, and other hard surfaces, persisting for months. Shared medical devices that move between patients are a known transmission route.
Standard hospital cleaning products don’t always kill it. The EPA maintains a specific list of disinfectants proven effective against Candida auris, which includes products based on hydrogen peroxide, bleach (sodium hypochlorite), and certain quaternary ammonium compounds. Facilities dealing with an outbreak need to use these specific products rather than relying on their routine cleaning protocols.
The fungus does not spread through the air like a cold or flu virus. You won’t catch it by walking through a hospital lobby or visiting a friend in the hospital. Transmission requires close, sustained contact in a care setting, or contact with contaminated surfaces and equipment.
Climate Change and New Fungal Threats
Candida auris isn’t the only fungal pathogen gaining ground. The broader trend of rising global temperatures may be making fungi more dangerous to humans. Most fungi can’t survive at human body temperature, around 98.6°F, which is one of our natural defenses. But as environmental temperatures climb, fungi may be adapting to tolerate warmer conditions, potentially including the warmth of the human body. Some researchers believe this thermal adaptation could be part of how Candida auris emerged as a human pathogen in the first place, appearing independently on multiple continents around the same time.
The WHO’s critical priority fungal pathogen list includes four species: Candida auris, Cryptococcus neoformans (which causes a deadly form of meningitis, primarily in people with HIV), Aspergillus fumigatus (a mold that causes severe lung infections), and the common yeast Candida albicans. Below that, the high priority group includes seven more, ranging from agents that cause deep tissue infections to molds that can invade the sinuses, lungs, and brain. Together, fungal infections kill more than 1.5 million people worldwide each year, a figure that has historically received far less attention than deaths from bacteria or viruses.
What This Means for You
If you’re generally healthy and not spending time in hospitals or long-term care facilities, Candida auris poses very little direct risk to you right now. The concern is broader: a drug-resistant organism spreading this quickly through healthcare systems puts strain on an already limited set of antifungal tools, and it raises the mortality risk for anyone who ends up seriously ill and hospitalized for other reasons.
If you or a family member is facing a long hospital stay, it’s reasonable to ask the care team what infection control measures are in place. Good hand hygiene by both staff and visitors remains the single most effective way to prevent transmission. For the general public, the most important thing to understand is that this is not a pandemic-style airborne threat. It is a healthcare-associated infection that’s growing steadily more common and more difficult to treat, and it’s being closely tracked by public health agencies for exactly that reason.